Sign in

    Mike Ryskin

    Managing Director and Senior Equity Research Analyst at BofA Securities

    Michael Ryskin is a Managing Director and Senior Equity Research Analyst at BofA Securities specializing in the Life Science Tools & Diagnostics and Animal Health sectors. He covers leading companies including Thermo Fisher Scientific, Icon PLC, and others and has maintained a 50.91% success rate on his stock recommendations according to TipRanks, ranking third in the 2024 Institutional Investor All-America Research Survey while his team ranked #1. Ryskin began his career as an oncology research scientist at Pfizer before transitioning to equity research at Merrill Lynch, joining BofA Securities in 2019. He holds a BA from Cornell University, an MA from Brown University, and an MBA from New York University, and is registered with FINRA and licensed for securities analysis.

    Mike Ryskin's questions to NEOGENOMICS (NEO) leadership

    Mike Ryskin's questions to NEOGENOMICS (NEO) leadership • Q1 2025

    Question

    Speaking on behalf of Mike Ryskin from BofA Securities, an analyst asked about how NeoGenomics is thinking about the evolution of the competitive landscape in the Minimal Residual Disease (MRD) market as it matures.

    Answer

    CEO Anthony Zook stated that the MRD market remains very attractive with low penetration, especially in the community setting, presenting a significant opportunity for NeoGenomics. CIO Andrew Lukowiak added that the market is in the 'early innings,' particularly regarding ultra-sensitive applications. He emphasized that NeoGenomics has an 'intellectual advantage' with in-house ctDNA pioneers, positioning the company to align with the market's evolution towards higher sensitivity over the next several years.

    Ask Fintool Equity Research AI